Accelerated Neuromodulation to Alleviate Cognitive Deficits Due to Cancer Therapy

Completed · Not applicable · Has a placebo group

Conditions studied: Cancer

In brief

This project is aimed at the discovery of neuro-modulation techniques that may alleviate chemotherapy induced cognitive deficits (CICD), especially in executive (higher-order) cognitive function (EF).

Key facts

Study ID

NCT04966520

Run by

Sneha Phadke

People needed

15

Starts

2021-06-01

Expected to finish

2023-07-18

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Women or men with a history of non-metastatic cancer who have completed definitive curative cancer therapy
• Received cytotoxic chemotherapy as a part of their therapy for cancer and at least one month has passed since the final cytotoxic chemotherapy treatment
• ≥ 18 years of age at time of cancer diagnosis and receipt of chemotherapy
• Patients must report subjective symptoms of "chemo-brain" (memory loss, difficulty with concentration, word-finding difficulties) with a FACT-Cog perceived cognitive impairment score < 60
• Ability to sign informed consent and comply with study procedures

You may not qualify if…

• Patients with a recurrence of cancer or those with current metastatic disease
• Patients with a history or current diagnosis of brain metastasis
• Patients with a history or current diagnosis of a primary brain tumor
• Patients with a history of brain surgery or brain radiation
• Patients receiving maintenance systemic therapy for cancer, other than endocrine therapy
• Patients who cannot produce or request adequate medical record documentation to ensure they meet inclusion and exclusion criteria
• Women who are currently pregnant
• History of childhood cancer or receipt of chemotherapy in childhood (<age 18). Developmental insult to the PFC, can be associated with long-term, durable and sometime debilitating cognitive deficits. Hence, we avoid any cognitive confounds that maybe related to this issue.
• Patients with a weight over 250 lbs., as these patients would not fit in the MRI scanner used in the protocol
• Patients who require benzodiazepines for MRI due to claustrophobic anxiety
• Patients with chest wall tissue expanders or other retained 7 Tesla MRI-incompatible metal. Any other specific contraindication to TMS or MRI not already listed above, including:
• (a) any implanted device in the head, neck or upper body (e.g. cochlear implant, cranial or other electrodes, pacemaker or defibrillator, medication pump, stent, aneurysm clip, etc.)
• (b) personal history of seizures or epilepsy, personal history of multiple concussions or unexplained loss of consciousness. This will be determined by physician judgement
• History of adverse reaction to previous TMS or MRI exposure
• Active substance use disorder in the past 6 months, excluding tobacco use disorder, as diagnosed by study physicians

Where it is running

• University of Iowa Hospitals & Clinics — Iowa City, Iowa, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.